Fusion Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview

Fusion Pharmaceuticals

13/03/2023 14:40

* Fusion Pharmaceuticals Inc  FUSN.OQ   FUSN.O  is expected
to show a fall in quarterly revenue when it reports  results on
March 15 (estimated). 
    * The Hamilton Ontario Ontario-based  company is expected to
report  a 97.1% decrease in revenue to $17 thousand from $594
thousand a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fusion
Pharmaceuticals
Inc is for a loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $12​, above​ its last closing price
of $4.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.51       -0.50      -0.55     Missed  -10
 Jun. 30 2022  -0.53       -0.53      -0.44     Beat    17.4
 Mar. 31 2022  -0.47       -0.48      -0.46     Beat    4.2​
 Dec. 31 2021  -0.42       -0.47      -0.40     Beat    14.3
 ​​Sep.        -0.61       -0.60      -0.45     Beat    24.7
 30 2021                                                
 Jun. 30 2021  -0.43       -0.39      -0.63     Missed  -61.5​
 Mar. 31 2021  -0.30       -0.29      -0.42     Missed  -43.2
 Dec. 31 2020  -0.19       -0.19      -0.32     Missed  -66.2
 This summary was machine generated March 13 at 14:40 GMT.  All
figures in US dollars  unless otherwise stated